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Abstract
Background: India has large PWID (persons who inject drugs) population estimated at 177,000. PWIDs are at high
risk for HIV, Hepatitis B (HBV) and Hepatitis C (HCV) infections. We report the prevalence of HIV, HBV and HCV
infections and correlates of HIV-HCV co-infection among male PWIDs in Delhi.
Methods: 3748 male PWIDs were recruited for a longitudinal HIV incidence study. Participants were tested for HBV
and HCV infections at their first follow-up visit (FV1) using serum HBV-surface antigen, and HCV-antibody tests
followed by HCV RNA PCR, respectively. All PWIDs who were HIV-negative at enrollment, were re-tested for HIV at FV1.
Multinomial logistic regression was employed to identify predictors of HIV, HCV and HIV-HCV co-infection.
Results: Overall prevalence of HIV, HBV and HCV among 2,292 participants tested at FV1 was 25.9 %, 9.7 % and 53.7 %,
respectively. 6.4 % of the participants had HIV mono-infection, 34.1 % had HCV mono-infection, and 19.6 % had
HIV-HCV co-infection. 26 % of HIV-positive participants without HCV were HBsAg positive.
In the regression model, having practiced at least one risky injection in the past month (relative risk ratio (RRR):
1.38; 95 % CI: 1.01-1.89) and not knowing his own HIV status (RRR: 1.65, 95 % CI: 1.25-2.17) were independent
predictors for HIV-HCV co-infection. Longer duration of drug injections was associated with a higher likelihood of
HCV mono-infection (2–5 years RRR: 2.13; 6–10 years RRR: 2.74; ≥11 years RRR: 3.14) and HIV-HCV co-infection
(2–5 years RRR: 5.14; 6–10 years RRR: 8.53; >11 years RRR: 8.03). Higher frequency of injection days/month was
associated with a higher likelihood of HCV mono-infection (≤10 days/month RRR: 1.61; 11–20 days/month RRR:
3.15; 21–30 days/month RRR: 3.47) and HIV-HCV co-infections (≤10 days/month RRR: 2.26; 11–20 days/month RRR:
3.46; 21–30 days/month RRR: 4.83).
Conclusions: We report a high prevalence of HIV, HCV and HIV-HCV co-infection among male PWIDs in Delhi. A
tenth of the participants were HBsAg positive. Targeted Intervention programs should make HBV/HCV testing,
prevention and care more accessible for PWIDs.
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Background
People who inject drugs (PWIDs) are at high risk for
blood-borne infections that include HIV, hepatitis B
(HBV) and C virus (HCV). HCV has been identified as
the most common viral infection affecting PWIDs [1]
and HCV is estimated to be 10 times more infectious
than HIV, per unit of blood required for transmission
[1]. Chronic HCV infection is associated with chronic
liver disease including cirrhosis and end-stage liver dis-
ease [2, 3]; about 80 % of individuals exposed to HCV
develop chronic infection and 3-11 % with chronic HCV
develop liver cirrhosis within 20 years [4]. HIV and HCV
co-infection adversely affect the course and prognosis of
both conditions [5–9]. In the case of HBV, 5 % of adults ex-
posed to the virus develop chronic HBV infection, and cir-
rhosis and death because of hepatocellular carcinoma are
important complications of chronic HBV infection [10, 11].
The HIV epidemic in India is concentrated among sex
workers, people who inject drugs (PWIDs), and men
who have sex with men – often called ‘most-at-risk-pop-
ulations’ (MARPs) - and among these groups PWIDs
have the second highest HIV prevalence in the country
(7.14 %) [12]. India has an estimated 177,000 PWIDs
[12]. The PWID population has been largely studied in
the high HIV prevalence states in north-eastern and
southern parts of the country, where HIV (25.4 -59.6 %),
HBV (10 %) and HCV (54.5-90.4 %) prevalence has been
reported [9, 13–15]. Although there is emerging evi-
dence of PWID presence in low HIV prevalence states
of the country (the north-western part), only a few stud-
ies have documented HIV (29-37 %), HBV (40 %) and
HCV (36-49 %) prevalence in these states [16–18]. The
PWID populations in the northeastern, southern, and
western parts of the country differ significantly on socio-
demographic characteristics, drug use patterns, and
awareness of HIV and hepatitis B and C infections [19]
highlighting the need for more epidemiological evidence
on the prevalence and correlates of hepatitis in the PWID
population. In this paper we report on the prevalence of
HIV and Hepatitis B and C infections in a large cohort of
male PWIDs from Delhi. Further we characterize the cor-




The Population Council, in collaboration with PATH’s
Arise - Enhancing HIV Prevention Programs for At-Risk
Populations, initiated a longitudinal cohort study, at five
Drop-in Centers (DICs) run by Sahara Centre for Re-
habilitation and Residential Care in Delhi, to examine HIV
incidence and behavior change among PWIDs, before and
after the provision of comprehensive HIV prevention inter-
ventions that follow WHO/UNAIDS/UNODC guidelines.
The study entailed three rounds of data collection: baseline,
follow-up visit 1 (FV1) and follow-up visit 2 (FV2); the me-
dian follow-up time between baseline and FV1 was
9.8 months (IQR: 8.2-11.1 months), and between FV1 and
FV2 was 12.0 months (IQR: 10.7-13.2 months). HIV testing
was undertaken at baseline to determine the HIV status of
the cohort [20]. At FV1, all participants underwent testing
for hepatitis B and C; HIV-negative participants also under-
went a second round of HIV testing at FV1. As funds were
available only for one round of hepatitis B and C testing, no
tests were conducted at FV2. In this paper we present data
from the FV1. Harm reduction services were initiated after
completion of FV1.
Participants were recruited through peer-referral and
targeted outreach by outreach workers (ORW). Prior to
study initiation, a mapping exercise was conducted to
identify all hotspots where PWIDs congregated in cen-
tral, east, north-east and north-west districts of Delhi
where the five Sahara Drop-in Centers (DIC) were lo-
cated. The peer-referral recruitment process was initi-
ated using eleven ‘seed’ participants (recruiters) across
the five study sites; each ‘seed’ participant was provided
with five recruitment coupons to give out to PWIDs in
their network. New recruits were linked to the recruiter
through unique ID numbers; each new recruit received
five coupons to recruit other PWIDs and the recruiter
received a ‘food coupon’ for each new PWID s/he
brought into the study. Food coupons were exchanged
for food at selected restaurant outlets. For recruitment
using targeted outreach, ORWs visited hotspots to invite
PWIDs to participate in the study and willing PWIDs
were directed to the study site with an ORW coupon.
All PWIDs who had a peer-referral recruitment coupon
were considered recruited through peer-referral while
those who came to the site with an ORW coupon were
listed as recruited by ORWs. Walk-in clients who did
not have either a peer-referral or ORW coupon were
also permitted to enroll. All PWIDs who enrolled in the
study, including walk-in clients and those recruited by
ORWs, received five recruitment coupons each to re-
cruit other PWIDs. Every hotspot was covered during
the recruitment phase and recruitment continued till no
new PWIDs could be found [21]. To be eligible, par-
ticipants had to be 18 years of age or older, current
IDU defined as injecting at least once in the last
3 months and residing in Delhi. All participants pro-
vided written informed consent. All participants received
Rs 40 (approximately 80 US cents) for participating in the
behavioral survey.
To detect duplicate registrations at recruitment, we
used a web-based, live data-base accessible by all five
DICs which allowed the DIC site manager to verify new
clients against already registered clients. Registration
procedures included the recording of photographs and
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the following identifiers: name, age, gender, marital sta-
tus, height, weight and fore-arm length – participants
presenting with similar identifiers were identified by the
computer program for further scrutiny [21].
At FV1, ORWs contacted participants in the commu-
nity to return for their follow-up visit. Returning partici-
pants completed FV1 data collection which included
laboratory testing and a behavioral survey. As very few
female PWIDs (n = 26) were recruited in the study, they
have been excluded from the analysis.
The study was approved by the National AIDS Control
Organization (NACO) Ethics Committee in Delhi, the
Research Ethics Committee of PATH in Seattle, USA
and the Institutional Review Board of the Population
Council in New York. All participants provided written
informed consent for participating in the behavioral sur-
vey and collection of blood samples.
Laboratory testing
HIV sero-status at baseline was determined using
NACO HIV testing guidelines via rapid tests: HIV-
negative status was based on a single highly sensitive
rapid test (DetermineTM HIV-1/2; Inverness Medical
Japan Co Ltd., Japan) and a positive result on two add-
itional confirmatory rapid tests (SignalTM HIV-1/2; Span
Diagnostics, Surat India and TridotTM; Biomed Indus-
tries, Himachal Pradesh, India). At FV1, all HIV-negative
male PWIDs were tested using a fourth generation
Antigen-Antibody test (ARCHITECT HIVAg/Ab Combo;
Abbott Laboratories, Illinois, USA) followed by a con-
firmatory Western Blot Assay (HIV Blot 2.2 Western blot
assay; MP Biomedicals Asia Pacific Limited, Singapore).
For participants with a negative or indeterminate result on
the Western blot test at FV1, a plasma HIV RNA PCR test
(COBAS® Ampliprep/COBAS® TaqMan® HIV-1 Test;
Roche Diagnostics, Tokyo, Japan) was conducted on the
FV1 plasma sample to identify any window period infec-
tion at FV1.
Hepatitis C antibodies were detected using CMIA/
Electrochemiluminescence test (ARCHITECT Anti-
HCV Reagent Kit; Abbott Laboratories, Illinois, USA).
All participants with a positive HCV antibody test
underwent HCV RNA PCR testing (COBAS® Ampli-
Prep/COBAS® TaqMan® HCV Tests; Roche Diagnos-
tics, Tokyo, Japan); participants positive for HCV
RNA were labelled HCV positive. We have considered
HCV RNA positivity as the marker for HCV preva-
lence so as to accurately identify active HCV infec-
tion and, therefore, PWIDs who have the potential to
transmit infection to others. HBV infection was de-
tected using serum hepatitis B surface antigen test
(ARCHITECT HBsAg Reagent Kit; Abbott Laboratories,
Illinois, USA).
Statistical analysis
All quantitative analyses were conducted using STATA
version 11.2 (Stata Corp, College Station, Texas, USA).
Participants were categorized into four groups with re-
gard to their HIV and HCV status: (a) Sero-negative
(HIV-, HCV-), (b) HIV mono-infection (HIV+, HCV-),
(c) HCV mono-infection (HIV-, HCV+), and (d) HIV &
HCV co-infection (HIV+, HCV+). Comparisons were
made between sero-negative participants (HIV- and HCV-
) and the different infection groups (HIV mono-infection,
HCV mono-infection, HIV & HCV co-infection) using
Chi-squared test for categorical variables and Mann–
Whitney U test for continuous variables. Prevalence of
HBV was reported in these four infection categories.
We used a multinomial logistic regression model to
predict the relative risk ratios for HIV mono-infection,
HCV mono-infection and HIV-HCV co-infection as
compared to the sero-negative PWIDs (reference cat-
egory). Variables that were found to be significant in at
least one of the infection categories from the bivariate
analysis from Table 1, were included in the regression
model (Table 2). Regional origin was classified into three
categories – Delhi, three adjacent states of Delhi (includes
neighboring states Uttar Pradesh, Haryana and Rajasthan),
and other states. HIV knowledge was assessed using a 6-
item index comprising knowledge that HIV transmission
can be prevented by (i) correct and consistent use of con-
doms for sex and (ii) having a monogamous uninfected
sexual partner; that (iii) sharing of needles/syringes in-
crease the risk of HIV transmission, that (iv-v) HIV infec-
tion cannot spread from mosquito bites or from sharing
food; and that (vi) healthy-looking people can be infected
with HIV. Comprehensive knowledge was considered to
be present if participants responded correctly on all 6
items. Prior knowledge of HIV status was also included.
Risky injection behavior was derived from a 5-item
index of various injection practices in the last month:
(i) using needles or syringes previously used by some-
one else, (ii) back/ front loading/splitting of drugs, (iii)
receiving an injection with a syringe filled by someone
else, (iv) drawing up drugs from a common container,
and (v) sharing vial, cooker, container, cotton, filter or
water with other injecting partners. A regular sex part-
ner was defined as a spouse or live-in partner. A paid
partner was someone the respondent had sex with in ex-
change for money, gifts or drugs. A non-regular partner
was someone the respondent was not living with or paid
for sex. Safe sex was defined as use of condoms every
time the respondent had sex. Unsafe sex was defined as
inconsistent or no use of condoms.
Results
A total of 3792 male PWIDs were recruited at baseline
[20]. Between baseline and FV1, 44 duplicate clients
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Table 1 Socio-demographic characteristics, risky injection and sexual behaviors and service utilization by male PWID by HIV, HCV and HIV-HCV co-infection status, Delhi (2012)
Total Sero-negative HIV mono-infected HCV mono-infected HIV & HCV co-infected
% (n) % (n) p-value1 % (n) p-value1 % (n) p-value1
Number of PWIDs 2,292 100.0 (916) 100.0 (146) 100.0 (781) 100.0 (449)
Prevalence of sero-infections (%) 40.0 6.4 34.1 19.6
Socio-demographic characteristics
Age (median, IQR) 29 (23, 37) 28 (23, 38.5) 26 (22, 35) 0.016 2 29 (24, 38) 0.873 2 30 (24, 35) 0.7722
Education 0.371 0.972
Illiterate 47.6 (1090) 46.8 (429) 48.6 (71) 46.3 (361) 51 (229) 2.8; 0.246
Class 1-6 27.6 (632) 27.4 (251) 30.8 (45) 27.6 (215) 27 (121)
7 or higher 24.8 (569) 25.8 (236) 20.6 (30) 26.2 (204) 22.1 (99)
Marital status 0.112 0.545 0.043
Married/cohabiting 34.7 (796) 36.7 (336) 30.1 (44) 34.8 (272) 32.1 (144)
Never married 52.9 (1213) 52.6 (482) 54.1 (79) 53 (414) 53 (238)
Divorced/widowed 12.4 (283) 10.7 (98) 15.8 (23) 12.2 (95) 14.9 (67)
Religion 0.921 <0.001 0.609
Hindu 62 (1418) 58.5 (535) 58.9 (86) 69.5 (541) 57 (256)
Non-Hindu 38 (870) 41.5 (380) 41.1 (60) 30.5 (237) 43 (193)
Regional origin 0.003 0.010 0.010
Delhi 25.4 (580) 25.4 (232) 24.7 (36) 25.4 (198) 25.4 (114)
3 states adjacent to Delhi 44.4 (1016) 39.9 (365) 53.4 (78) 46.2 (360) 47.4 (213)
Others 30.2 (692) 34.7 (317) 21.9 (32) 28.4 (221) 27.2 (122)
Duration of residence in Delhi (median, IQR) 22 (15, 30) 22 (15, 30) 20 (12, 29) 0.142 2 23 (16, 30) 0.124 2 23 (15, 30) 0.208 2
Accommodation 0.183 0.879 0.801
Living at home with family 44 (1009) 44.4 (407) 39.7 (58) 44.4 (347) 43.9 (197)
Living In rented/paying guest 17.5 (400) 17.6 (161) 14.4 (21) 18.4 (144) 16.5 (74)
Living on the street 38.5 (883) 38 (348) 45.9 (67) 37.1 (290) 39.6 (178)
Comprehensive HIV knowledge 0.190 0.908 0.048
No/incomplete knowledge 63.2 (1448) 64.5 (591) 58.9 (86) 64.8 (506) 59 (265)
Complete knowledge 36.8 (844) 35.5 (325) 41.1 (60) 35.2 (275) 41 (184)
Alcohol use 0.046 0.859 0.009
Never 54.4 (1246) 51.9 (475) 61 (89) 53.1 (414) 59.8 (268)
2 times/week or less 35.6 (815) 37.1 (339) 33.6 (49) 35.8 (279) 33 (148)
3 times a week or more 10 (228) 11 (101) 5.5 (8) 11.2 (87) 7.1 (32)
Sex with regular or paid/non-regular female partner in last 3 months 0.008 0.110 <0.001














Table 1 Socio-demographic characteristics, risky injection and sexual behaviors and service utilization by male PWID by HIV, HCV and HIV-HCV co-infection status, Delhi (2012)
(Continued)
Safe sex 11 (251) 12.3 (113) 8.2 (12) 10.5 (82) 9.8 (44)
Unsafe sex 25.6 (586) 30 (275) 20.6 (30) 26.9 (210) 15.8 (71)
Service utilization in the last 3 months
Accessed NSP services <0.001 <0.001 <0.001
No 55.5 (1271) 70.4 (645) 43.2 (63) 48.9 (382) 40.3 (181)
Yes 44.6 (1021) 29.6 (271) 56.9 (83) 51.1 (399) 59.7 (268)
Accessed detox/rehab services 0.696 0.270 0.148
No 94.1 (2157) 93.3 (855) 92.5 (135) 94.6 (739) 95.3 (428)
Yes 5.9 (135) 6.7 (61) 7.5 (11) 5.4 (42) 4.7 (21)
Accessed OST services 0.847 0.643 0.583
No 89.3 (2046) 89.2 (817) 89.7 (131) 89.9 (702) 88.2 (396)
Yes 10.7 (246) 10.8 (99) 10.3 (15) 10.1 (79) 11.8 (53)
Duration and frequency of injection drug use
Time since first injection <0.001 <0.001 <0.001
1 year or less 13.2 (299) 22.5 (204) 9.7 (14) 8.6 (66) 3.4 (15)
2-5 years 53.8 (1221) 52.7 (478) 54.5 (79) 55.1 (425) 53.6 (239)
6-10 years 21.6 (490) 15.9 (144) 27.6 (40) 22.5 (174) 29.6 (132)
11 years or more 11.5 (260) 8.9 (81) 8.3 (12) 13.9 (107) 13.5 (60)
Number of days injected in the past month <0.001 <0.001 <0.001
Not injected 26.5 (606) 44.4 (406) 19.2 (28) 15.7 (122) 11.1 (50)
1-10 days 20.5 (470) 23.5 (215) 16.4 (24) 18.2 (142) 19.8 (89)
11-20 days 16.7 (382) 11.4 (104) 17.1 (25) 21.2 (165) 19.6 (88)
21-30 days 36.3 (830) 20.7 (189) 47.3 (69) 44.9 (350) 49.4 (222)
Risky injection behavior in the past 1 month <0.001 <0.001 <0.001
No risk 47.6 (1090) 63.7 (583) 39 (57) 37.6 (294) 34.7 (156)
At least one risky injection 52.4 (1202) 36.4 (333) 61 (89) 62.4 (487) 65.3 (293)
Prior HIV test
Prior knowledge of own HIV status 0.001 0.778 <0.001
Know the result 71.4 (1631) 74.5 (681) 61 (89) 73.9 (575) 64.1 (286)
Not tested/ Result not known 28.6 (653) 25.5 (233) 39 (57) 26.1 (203) 35.9 (160)
1 Chi-squared test, unless specified, for each infection category compared with sero-negative participants
2 Mann–Whitney U test for each infection category compared with sero-negative participants














were identified and removed from the database. Of
the remaining male PWIDs 66.2 % (2480/3748) par-
ticipants returned for their FV1; the behavioral survey
and blood tests were conducted for 2353 participants
(Fig. 1). As shown in Fig. 1, HIV test results were
available for 2348 participants, hepatitis B for 2312
participants and hepatitis C test results for 2294 par-
ticipants. Our data analysis includes the 2292 male
PWIDs for whom we have HIV, HBV and HCV test
results.
The median age of study participants was 29 years
(IQR: 23–37). Most of them were illiterate (48 %), never
married (53 %), and of the Hindu faith (62 %). All partic-
ipants resided in Delhi, however, 44 % were originally
from the three adjacent states of Delhi and 33 % from
other states (Table 1). While most of the participants
were home-based (44 %), a sizeable proportion lived on
the streets (39 %). HIV knowledge was low (37 %); 54 %
reported never having consumed alcohol and 63 % had
been sexually inactive in the last 3 months. Only 9.1 %
Table 2 Multinomial Logistic Regression analysis to determine predictors of HIV, HCV and HIV-HCV prevalence among Male PWID in
Delhi (2012)1, 2
HIV mono-infection HCV mono-infection HIV & HCV co-infection
RRR (95 % CI); p-value RRR (95 % CI); p-value RRR (95 % CI); p-value
Comprehensive HIV knowledge
No comprehensive knowledge 1.00 1.00 1.00
Having comprehensive knowledge 1.50 (1.03 - 2.20); 0.037 1.08 (0.86 - 1.34); 0.523 1.47 (1.13 - 1.91); 0.004
Alcohol use
Never 1.00 1.00 1.00
≤2 times/week 0.85 (0.57 - 1.27); 0.432 0.96 (0.77 - 1.21); 0.759 0.88 (0.67 - 1.16); 0.363
≥3 times a week 0.62 (0.28 - 1.36); 0.236 1.27 (0.89 - 1.81); 0.18 0.85 (0.53 - 1.36); 0.486
Sex with any female partner in last 3 months3
No sex 1.00 1.00 1.00
Safe sex 0.55 (0.29 - 1.06); 0.076 0.79 (0.56 - 1.11); 0.17 0.62 (0.41 - 0.95); 0.026
Unsafe sex 0.60 (0.37 - 0.99); 0.046 0.93 (0.71 - 1.21); 0.567 0.40 (0.28 - 0.57); <0.001
Accessed NSP services last 3 months
No 1.00 1.00 1.00
Yes 1.91 (1.26 - 2.89); 0.002 1.37 (1.08 - 1.73); 0.009 1.74 (1.32 - 2.30); <0.001
Duration of injecting drug use
≤1 year 1.00 1.00 1.00
2-5 years 1.90 (1.02 - 3.51); 0.042 2.13 (1.53 - 2.95); <0.001 5.14 (2.91 - 9.09); <0.001
6-10 years 3.01 (1.52 - 5.97); 0.002 2.74 (1.86 - 4.03); <0.001 8.53 (4.65 - 15.64); <0.001
11 years of more 2.07 (0.86 - 5.00); 0.106 3.14 (2.00 - 4.93); <0.001 8.03 (4.09 - 15.76); <0.001
Frequency of injection during the past month
Never 1.00 1.00 1.00
1-10 days 0.93 (0.47 - 1.83); 0.831 1.61 (1.14 - 2.29); 0.007 2.26 (1.43 - 3.57); <0.001
11-20 days 1.57 (0.76 - 3.24); 0.226 3.15 (2.12 - 4.66); <0.001 3.46 (2.09 - 5.74); <0.001
21-30 days 2.47 (1.30 - 4.69); 0.006 3.47 (2.43 - 4.95); <0.001 4.83 (3.06 - 7.61); <0.001
Risky injection practice in last one month
Never 1.00 1.00 1.00
At least one risky injection 1.40 (0.87 - 2.26); 0.171 1.39 (1.06 - 1.83); 0.016 1.38 (1.01 - 1.89); 0.045
Prior knowledge of own HIV status4
Know the result 1.00 1.00 1.00
Not tested/Don't know the result 1.92 (1.31 - 2.82); 0.001 0.97 (0.76 - 1.23); 0.813 1.65 (1.25 - 2.17); <0.001
1Reference category of the dependent variable in the multinomial regression model is sero-negative participants (n = 916) compared to participants with HIV
mono-infection (n = 146), HCV mono-infection (n = 781) and HIV & HCV co-infection (n = 449)
2Controlled for age, religion, marital status and regional origin
3Any female partner includes regular, non-regular or paid
4At baseline
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of participants had ever heard of hepatitis B and 3.1 % had
heard of hepatitis C infections (data not shown). A third
had been injecting for more than 6 years. Unsafe injection
practices were common: 26.6 % reported injecting with a
used needle in the last one month, 32 % had shared inject-
ing equipment, 15.4 % had received a prefilled injection
from another PWID, 18.3 % had injected drugs using front/
back loading and splitting and 48.1 % had drawn drugs
from a common container (data not shown); overall 52.4 %
participants reported risky injection behavior in the last one
month (Table 1). 44.5 % had accessed needle/syringe ex-
change/distribution services in the last 3 months, while up-
take of oral substitution therapy (OST) and rehabilitation
services was low (Table 1). The vast majority of participants
(69.2 %) reported having injected opioids (heroin/brown
sugar/smack/synthetic opioids) and 73.4 % had injected
tranquilizers/antihistaminics in the last one month; a few
reported injecting cocaine (0.5 %) and amphetamines
(3.1 %). Participants typically injected a cocktail of two or
three drugs consisting of one opioid and tranquilizers and/
or antihistaminics (data not shown).
Prevalence of HIV, HCV and HIV-HCV co-infection
HCV antibody tests were positive for 70.9 % (1626/2294) of
the participants; of those 75.7 % (1230/1626) participants
tested positive on HCV RNA PCR test, and were consid-
ered HCV positive; overall 53.7 % (1230/2292) of partici-
pants were HCV RNA positive. Overall 6.4 % (n = 146)
participants had HIV mono-infection, 34.1 % (n = 781) had
HCV mono-infection and 19.6 % (n = 449) HIV & HCV
co-infection while 39.9 % were sero-negative for HIV or
HCV. HIV prevalence was 25.9 % (595/2292); this includes
the 109 new seroconversions among HIV-negative PWIDs
documented between baseline and FV1. Table 1 highlights
the differences between the various infection groups
compared to uninfected participants. On bivariate ana-
lysis, there were no significant differences between vari-
ous infection groups and uninfected participants on
age, education, duration of residence in Delhi or ac-
commodation. All three infection groups were more
likely to have migrated from the 3 states adjacent to
Delhi. HIV & HCV co-infected participants were more
likely to have comprehensive HIV knowledge, report
non-consumption of alcohol, be divorced/widowed and
not sexually active in the last 3 months than sero-
negative participants. HIV mono-infected participants
were also more likely to be not sexually active. All three
infection groups were more likely to have been inject-
ing for longer periods (>2 years) and on more days
every month, to have higher scores on the risky
Fig. 1 Follow-up and Laboratory testing of Male PWIDs in the baseline full Cohort
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injection index and to have accessed NSP services than
uninfected participants (Table 1).
Prevalence of HBV, HIV-HBV and HBV-HCV co-infections
Hepatitis B surface antigen was detected in 9.7 % (222/
2292) participants. HBV prevalence was 6.7 % (52/781)
among the HCV mono-infected and 8.7 % (39/449)
among the HIV-HCV co-infected participants. The high-
est HBV prevalence (26 %; 38/146) was found among
those who were HIV positive but HCV negative. The
prevalence of HBV mono-infection was 10.2 % (93/916).
Results from multivariate multinomial logistic regression
Results of multinomial logistic regression analysis to de-
termine correlates of HIV mono-infection, HCV mono-
infection, and HIV & HCV co-infection with reference
to uninfected participants, after controlling for age,
marital status, religion and regional origin, are presented
in Table 2. Participants who had not undertaken HIV
testing or did not know of their HIV-status prior to the
study were at higher risk of HIV mono-infection (RRR:
1.92) and HIV-HCV co-infection (RRR: 1.65). Longer
duration of drug injections was associated with a higher
likelihood of HCV mono-infection with a dose response ef-
fect (2–5 years RRR: 2.13; 6–10 years RRR: 2.74; >11 years
RRR: 3.14 years) and HIV-HCV co-infection (2–5 years
RRR: 5.14; 6–10 years RRR: 8.53; >11 years RRR: 8.03). A
higher frequency of injection days/month was associated
with a higher likelihood, with a dose–response effect, for
HCV mono-infection (≤10 days/month RRR: 1.61; 11–20
days/month RRR: 3.15; 21–30 days/month RRR: 3.47) and
HIV-HCV co-infections (≤10 days/month RRR: 2.26; 11–20
days/month RRR: 3.46; 21–30 days/month RRR: 4.83).
Risky injection behavior in the last one month was an inde-
pendent predictor of HCV mono-infection (RRR: 1.39) and
HIV-HCV co-infection (RRR: 1.38).
Having comprehensive HIV knowledge was associated
with a higher risk of HIV mono-infection (RRR: 1.5) and
HIV-HCV co-infection (RRR: 1.47). Further, a higher
likelihood of all three categories of infection was ob-
served among participants who had accessed needle syr-
inge program services in the last three months (HIV
mono-infection RRR: 1.91; HCV mono-infection RRR:
1.37; HIV-HCV co-infection RRR: 1.74). These results
are unexpected and need to be interpreted with caution.
On further analysis, it was observed that (a) comprehen-
sive HIV knowledge increased with longer duration of
injection use (<1 year: 27 %; 2–5 years: 36 %; 6–10 years:
41 %; >11 years: 45 %; p < 0.001); (b) the use of needle
syringe program services increased with longer duration
of injection drug use (<1 year: 27 %; 2–5 years: 44 %; 6–
10 years: 54 %; >11 years: 53 %; p < 0.001) and frequency
of injections in the last 1 month (no injection: 8 %; 1–10
days: 48 %; 11–20 days: 63 %; 21–30 days: 62 %; p <
0.001); and (c) among PWIDs who accessed NSP services,
risky injection practices increased with greater frequency
of injections in last 1 month (no injections: 1.92 %; 1–10
days: 65.9 %; 11–20 days: 76.9 %; 21–30 days: 79.1 %; p <
0.001). However, comprehensive HIV knowledge was not
associated with use of needle syringe programs services:
44 % of participants with comprehensive knowledge and
46 % without comprehensive knowledge had accessed nee-
dle syringe program services in the last 3 months (p =
0.26). Public sector HIV prevention services delivered
through Targeted Intervention (TI) programs for PWIDs
in Delhi have been in existence for several years. PWIDs
with longer duration of injections are more likely to be a
part of the PWID community for a longer period of time,
and therefore, more likely to be covered by NSP and IEC
services. PWIDs with a higher frequency of injections are
more likely to seek NSP services due to a greater need for
clean needles. Therefore, PWIDs with longer duration of
injecting and greater frequency of injections remain most
at risk for new infections despite accessing NSP services
as they may not obtain a sufficient supply of clean needles
to meet their need, and continue to engage in unsafe injec-
tion practices as shown. Needle syringe distribution as
part of our study was initiated only after completion of
FV1.
Any sex (safe sex RRR: 0.62 and unsafe sex RRR: 0.40)
compared to no sex was associated with a lower likeli-
hood of HIV-HCV co-infection; unsafe sex (RRR: 0.60)
was also associated with a lower likelihood of HIV
mono-infection. In our cohort, only 37 % of the partici-
pants were sexually active; sexual activity decreased with
duration of injection drug use (≤1 year: 45 %; 2–5 years:
36 %; 6–10 years: 36 %; ≥11 years: 35 %; p = 0.052) and
frequency of injections in the last 1 month (no injection:
41 %; 1–10 days: 41 %; 11–20 days: 35 %; 21–30 days:
32 %; p < 0.004). Thus, the risk of HIV and HCV infec-
tion in our cohort was mainly concentrated around in-
jection behaviors and not sexual behavior. Among the
sexually active PWIDs, 70 % (586/837) reported unsafe
sex in the last 3 months. Unsafe sex among PWIDs re-
mains a key programmatic concern.
Discussion
In this paper, we report a high prevalence of HIV infec-
tion (25.9 %), hepatitis C infection (53.7 %), and more
significantly, high HIV-HCV co-infection (19.6 %)
among male PWIDs in Delhi in 2012. HBV prevalence
was lower at 9.7 %; while HIV-HBV co-infection was
3.4 % overall, among HIV positive PWIDs without HCV
the prevalence was 26 %. Our findings are at variance
with a study conducted among PWIDs in Delhi in 2003
[16], which reported a prevalence of 37 % for HIV, 36 %
for HCV infection, HIV-HCV co-infection of 9.6 % and
40 % prevalence for HBV. The annual HIV Sentinel
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Surveillance (HSS) [22] has documented a change in
HIV prevalence among PWIDs in Delhi from 14.4 % in
2003, 10 % in 2006 to 18.2 % in 2010–11. The HSS is an
annual exercise to monitor trends in HIV prevalence;
HIV testing is conducted among 250 PWIDs, recruited
through snowball sampling at two DICs in Delhi. One
DIC overlaps geographically with one of our study sites.
Our HIV, HBV and HCV prevalence are similar to those
reported more recently from Chennai [9] with a HIV
prevalence of 29.8 %, HCV prevalence of 62.1 % and
11.1 % for HBV; and a recent study from Delhi that re-
ports a HIV prevalence of 13.8 %; HCV mono-infection
of 31 % and HIV-HCV co-infection of 14.5 % [23]. An-
other recent study from Punjab reports a similarly high
prevalence of HIV (29 %), HCV prevalence of (49 %)
and HIV-HCV co-infection 25.7 % among PWIDs [18].
Existing reports about HCV prevalence are based pre-
dominantly on serological testing for anti HCV anti-
bodies, and a positive result can represent an acute,
chronic or resolved HCV infection [8, 16, 18, 23–26]. We
report the prevalence of active HCV infection based on
HCV RNA PCR testing; to the best of our knowledge this
is the first study in the country to provide these estimates
for a large cohort of PWIDs. This has relevance for the
national program as only PWIDs with active HCV infec-
tion need treatment. Our finding that a quarter of the
PWID with a positive HCV antibody test were negative
for HCV RNA, suggests that existing studies, which pre-
dominantly used antibody test to report HCV prevalence,
overestimate infections substantially.
Several studies report a higher HCV prevalence among
PWIDs than HIV prevalence [9, 18, 25, 26]. HCV is esti-
mated to be 10 times more infectious than HIV, per unit
of blood required for transmission [27] and recent evi-
dence showing that HCV can remain infectious, after
drying at room temperature, for up to six weeks in blood
spots [28], may provide a biological explanation for the
continuing spread of HCV among PWIDs as they con-
tinue to practice unsafe injection practices that include
sharing equipment, drawing from a common container
and injecting with used needles.
HBV prevalence was lower overall (9.7 %). The preva-
lence among the HIV positive PWIDs (12.8 %), including
those with HCV infection, was similar to the 12 % re-
ported by Solomon et al., from Chennai [8]. However, it
is noteworthy that HBV prevalence among HIV-positive
participants, in the absence of HCV, was 26 %. A study
conducted in Manipur among HIV-positive PWIDs de-
tected HB core antibodies, a marker of prior infection, in
all their participants implying that all had been exposed
to HBV in the past [14]. Most studies have used HBsAg
as the marker of HBV [8, 16]; it is possible that in the
presence of a high prevalence of active HCV infection, all
HBV infections may not be detected using HBs antigen
testing. HBsAg is a marker of acute infection that persists
during chronic infection. However, in some patients with
acute infection (1-5 %) and in the rare chronic low-level
carrier, levels of HBsAg may be too low to be detected by
standard assays and other tests may be required [29]. It is
well documented that in dual infections, HBV and HCV
interact, and affect immune responses. Available evi-
dence demonstrates that the two viruses can inhibit each
other simultaneously; the chronology of infection has a
role in determining the dominant virus; and HBV and
HCV can alternate their dominance [30–32]. However,
the overall dominant effect in published literature ap-
pears to be HCV suppression of HBV. Furthermore, pa-
tients with chronic HCV may have occult or silent HBV
infection with low levels of circulating HBV DNA, and
lack the HBsAg and HBeAg markers and their antibodies
[30, 33]. Undetected HBV is a concern as the virus can
be transmitted through percutaneous, sexual and
mother-to-child routes. Future studies should consider
using a wider panel of tests to determine HBV prevalence
in this high risk population, as a one-time HBsAg test
may underestimate prevalence.
As HBV and HCV co-infected patients have a higher
risk of progressing to fulminant hepatitis, developing
chronic infection, cirrhosis and hepatocellular carcinoma
[2, 11], it is extremely important for targeted interven-
tion programs for PWIDs to include HBV and HCV in
prevention messages and counselling protocols for
PWIDs and their families. TI programs should include
HBV testing and vaccination, an effective prevention
intervention. As there is no vaccine available for HCV
and it may be a while before treatment becomes afford-
able and available through public health programs, the
focus of primary prevention efforts should continue to
be on safe injection practices in this population.
Unsafe injection practices, duration of injection drug
use and frequency of injections were the main predictors
for HCV mono-infection and HIV-HCV co-infection.
Accessing NSP services in the last 3 months was associ-
ated with a higher risk of HIV mono-, HCV mono- and
HIV-HCV co-infections and having comprehensive HIV
knowledge was associated with higher risk of HIV-HCV
co-infection. These findings must be interpreted with
caution. Further analysis showed that the use of NSP
services and having HIV knowledge increased with lon-
ger duration of injection drug use, and higher frequency
of injections. It is very likely that PWIDs who had been
injecting for longer periods and were injecting more fre-
quently were more aware of harm reduction programs
in the area, had a greater need for needles/syringes and
had been exposed to IEC activities in the area, and
therefore, were accessing NSP services. At the same
time, more than half the participants continued unsafe
injection practices in the last one month, especially,
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those who injected more frequently and accessed NSP
services. It is possible that they are unable to obtain a
sufficient supply of needles to meet their need. Thus, the
main risk of infection remains rooted in unsafe injection
practices, longer duration of injection drug use and
more frequent injections. In our baseline findings, HIV
positive participants reported higher risk behaviors and
accessed NSP services more often [20]. As this is a
prevalence study we cannot comment on when the in-
fections occurred; thus, it is also very likely that among
long duration PWIDs the infections may have occurred
before participants started accessing NSP services. The
majority of our participants were not sexually active
(63 % overall and 74.3 % among HIV-HCV co-infected
participants) and sexual activity was not associated with
increased HIV, HCV or HIV-HCV co-infection. How-
ever, among PWIDs who were sexually active, 70 % re-
ported unsafe sex in the last 3 months, which remains
an important concern for the HIV prevention program.
More than half our study participants had never con-
sumed alcohol. This is in contrast to findings from a
2012 study on drug use patterns across 11 states that re-
ports the majority of PWIDs ever used alcohol in their
lifetime [34]. It is possible that our study participants
transitioned to injection drug use from other addictions
without consuming alcohol. In our previous study with 800
PWID in Delhi, only 23 % reported alcohol consumption
[19]. Overall alcohol consumption in the general popula-
tion in Delhi is low – 33.1 % of men 15–49 years of age
interviewed in NFHS-3 reported consuming alcohol [35].
The study is not without limitations. Just two-thirds
(66.2 %) of our cohort returned for this follow up visit;
while this does not impact the reporting of prevalence
for HIV, HBV and HCV infections, the program would
have benefitted from prevalence reported from the larger
cohort. We used only HBsAg testing to detect HBV in-
fection. Using a wider panel of tests may have allowed
us to detect occult HBV infections or past exposures;
this may be considered for future studies. Further, we
would have benefited from follow-up HBV and HCV
testing at FV2, in this cohort of PWIDs, to obtain inci-
dence rates that would have provided important infor-
mation for the program; unfortunately we could not do
so due to resource constraints. Despite using multiple
strategies to reach female PWIDs including female seeds
for peer-referral and female out-reach workers, we were
able to recruit only 26 female PWIDs. In our previous
study in 2006, we used respondent-driven sampling and
were able to only recruit 17 female PWIDs [19]. It is very
likely that there are few female PWIDs in Delhi. This find-
ing has also been reported from other parts of India and
in Asian countries [9, 36]. Anecdotal information from
ORWs in Delhi suggests that non-injecting drug-use is
more frequent among female drug users; further research
with female non-injecting drug users is needed to better
understand drug use in this population.
Conclusion
In conclusion, we report a high prevalence of HIV, HCV
and HIV-HCV co-infection among male PWIDs in
Delhi. The prevalence of HBV, although lower than
HCV, is still high with nearly a tenth of the PWIDs car-
rying the virus. The PWID population continues to en-
gage in unsafe injection practices and not access NSP
services regularly. Targeted intervention programs need
to urgently address this problem by including hepatitis B
and C in HIV prevention messages and counseling, ex-
pand services to include hepatitis testing, and offer
hepatitis B vaccination for HBV negative PWIDs. A push
by governments and activists to reduce the cost of treat-
ment for hepatitis C is also needed to widen access to
treatment for infected persons.
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